文献速递帕金森病与运动障碍认知障碍与痴呆

α4β2*烟碱型胆碱能受体靶点结合在帕金森病步态平衡障碍中的研究

α4β2* Nicotinic Cholinergic Receptor Target Engagement in Parkinson Disease Gait-Balance Disorders.
PubMed 文献 · Ann Neurol · 2021-05-26

本研究在伴有胆碱能缺陷的非痴呆帕金森病患者中,使用[18F]flubatine PET评估口服伐尼克兰后α4β2*烟碱型乙酰胆碱受体的占有率,并在双盲安慰剂对照交叉试验中评估伐尼克兰对步态、平衡和认知的影响。结果显示伐尼克兰占据60%至70%受体,对姿势稳定性无显著影响但使常速步态速度减慢,同时缩小双任务与单任务步态速度差异、降低双任务成本并改善持续注意力测试表现。

要点

  • 伐尼克兰占据60%至70%的α4β2*烟碱型乙酰胆碱受体。
  • 伐尼克兰对姿势稳定性无显著影响,但使常速步态速度减慢。
  • 伐尼克兰缩小双任务与单任务步态速度差异,改善持续注意力。

核心结论

  • 伐尼克兰占据α4β2*烟碱型乙酰胆碱受体,耐受性良好,增强注意力并改变步态表现。
  • 结果与靶点结合一致,α4β2*激动剂可能值得进一步评估用于缓解帕金森病步态和平衡障碍。

研究设计与样本

  • 非痴呆伴胆碱能缺陷的帕金森病患者,经[18F]氟乙氧基苯扎米考酚PET识别。
  • 用[18F]flubatine PET测量亚急性口服伐尼克兰后的α4β2*烟碱型乙酰胆碱受体占有率。
  • 28名参与者经血浆伐尼克兰浓度确认治疗依从性,获得相同结论。

主要发现

  • 伐尼克兰剂量0.25mg每日一次、0.25mg每日两次、0.5mg每日两次和1.0mg每日两次产生60%至70%受体占有率。
  • 伐尼克兰对姿势稳定性测量无显著影响,并导致常速步态速度减慢。
  • 伐尼克兰缩小双任务与无双任务步态条件下常速步态速度的差异,降低双任务成本,改善持续注意力测试表现。

关键数值与推荐

  • 伐尼克兰剂量0.25mg每日一次、0.25mg每日两次、0.5mg每日两次和1.0mg每日两次产生60%至70%受体占有率。
  • 交叉研究选择0.5mg口服每日两次。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Attentional deficits following degeneration of brain cholinergic systems contribute to gait-balance deficits in Parkinson disease (PD). As a step toward assessing whether α4β2* nicotinic acetylcholine receptor (nAChR) stimulation improves gait-balance function, we assessed target engagement of the α4β2* nAChR partial agonist varenicline. METHODS: Nondemented PD participants with cholinergic deficits were identified with [18 F]fluoroethoxybenzovesamicol positron emission tomography (PET). α4β2* nAChR occupancy after subacute oral varenicline treatment was measured with [18 F]flubatine PET. With a dose selected from the nAChR occupancy experiment, varenicline effects on gait, balance, and cognition were assessed in a double-masked placebo-controlled crossover study. Primary endpoints were normal pace gait speed and a measure of postural stability. RESULTS: Varenicline doses (0.25mg per day, 0.25mg twice daily [b.i.d.], 0.5mg b.i.d., and 1.0mg b.i.d.) produced 60 to 70% receptor occupancy. We selected 0.5mg orally b.i.d for the crossover study. Thirty-three participants completed the crossover study with excellent tolerability. Varenicline had no significant impact on the postural stability measure and caused slower normal pace gait speed. Varenicline narrowed the difference in normal pace gait speed between dual task and no dual task gait conditions, reduced dual task cost, and improved sustained attention test performance. We obtained identical conclusions in 28 participants with treatment compliance confirmed by plasma varenicline measurements. INTERPRETATION: Varenicline occupied α4β2* nicotinic acetylcholine receptors, was tolerated well, enhanced attention, and altered gait performance. These results are consistent with target engagement. α4β2* agonists may be worth further evaluation for mitigation of gait and balance disorders in PD. ANN NEUROL 2021;90:130-142.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Albin RL, Müller MLTM, Bohnen NI, et al. α4β2* Nicotinic Cholinergic Receptor Target Engagement in Parkinson Disease Gait-Balance Disorders. Ann Neurol. 2021. PMID: 33977560. doi:10.1002/ana.26102

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。